Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience

I Elomaa, C Blomqvist, G Saeter, Mef Nilbert, O R Monge, Thomas Wiebe, Thor Alvegård

Research output: Contribution to journalArticlepeer-review


During the past 15 years the Scandinavian Sarcoma Group has treated 140 patients with Ewing's sarcoma. Two protocols have been used. SSG IV included 52 patients between 1984 and 1990 and SSG IX, 88 patients since 1990. After 5 years of treatment, local recurrences occurred in 19% of the patients (M0 + M1) in the SSG IV group and 10% in the SSG IX group. Distant metastases developed in 57% of the M0-patients in the SSG IV group and in 33% in the SSG IX group. Tumor-related survival (overall) of M0-patients was 49% in SSG IV and 70% in SSG IX, and the metastasis-free survival rate 45% and 58%, respectively. Patients having a localized extremity tumor had a survival rate of 90% (SSG IX). In both treatment groups, good responders to chemotherapy had a better survival rate than poor ones (SSG IV, p < 0.02, GI-II vs. G II-IV and SSG IX, p < 0.003, GI-III vs. G IV). In conclusions local control and survival rates were better with SSG IX than SSG IV.
Original languageEnglish
Pages (from-to)69-73
JournalActa Orthopaedica Scandinavica. Supplementum
Issue number285
Publication statusPublished - 1999

Subject classification (UKÄ)

  • Cancer and Oncology


Dive into the research topics of 'Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience'. Together they form a unique fingerprint.

Cite this